The present consensus [1] represents an individualized, pragmatic, and practice-oriented guideline aimed at reducing cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). In summary, we consider it important to emphasize that cardiovascular care in these patients is a continuous process, which we have therefore structured into three phases. Achieving sustained remission appears to be one of the most important cardioprotective measures. In the future, an improvement in the level of evidence is certainly desirable, possibly through the standardization of study endpoints. However, in order to formulate recommendations for risk reduction across all rheumatic diseases, clarity regarding the pathomechanisms of myocardial ischemia in the context of the respective underlying diseases is required. A future vision would certainly be the development of a joint strategy among different medical societies whose patients are affected by an increased cardiovascular risk, such as rheumatology, gastroenterology, dermatology, and nephrology.
